Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Sunday
May 08
10:30 - 11:30
Mini-Oral Theatre 2
14: Urology
Luca Nicosia, Italy;
Pirus Ghadjar, Germany
Mini-Oral
Clinical
Estimates of α/β ratios for individual late urinary toxicity endpoints: analysis of a cohort trial
MO-0557

Abstract

Estimates of α/β ratios for individual late urinary toxicity endpoints: analysis of a cohort trial
Authors:

Tiziana Rancati1, Eliana Gioscio1, Alessandro Cicchetti1, Barry Rosenstein2, Petra Seibold3, Barbara Avuzzi4, David Azria5, Ananya Choudhury6, Dirk De Ruysscher7, Alison M. Dunning8, Rebecca Elliott6, Sarah Kerns9, Maarten Lambrecht10, Elena Sperk11, Paul Symonds12, Christopher Talbot13, Ana Vega14, Liv Veldeman15, Riccardo Valdagni16, Adam Webb13, Jenny Chang-Claude17, Catharine West6

1Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program, Milan, Italy; 2Icahn School of Medicine at Mount Sinai, Department of Radiation Oncology, New York, USA; 3German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Division of Radiation Oncology 1, Milan, Italy; 5University Federation of Radiation Oncology, Montpellier Cancer Institute, Department of Radiation Oncology, Montpelllier, France; 6University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Translational Radiobiology Group, Division of Cancer Sciences, Manchester, United Kingdom; 7GROW Institute for Oncology and Developmental Biology, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands; 8Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Labs, Department of Oncology, Cambridge, United Kingdom; 9University of Rochester Medical Center, Rochester, Departments of Radiation Oncology and Surgery, New York, USA; 10University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium; 11Heidelberg University, Mannheim, Medical Faculty Mannheim, Mannheim, Germany; 12Leicester Cancer Research Centre, University of Leicester, Department of Radiation Oncology, Leicester, United Kingdom; 13Leicester Cancer Research Centre, University of Leicester, Department of Genetics and Genome Biology, Leicester, United Kingdom; 14Fundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica (USC), Santiago de Compostela, Spain; 15Ghent University Hospital, Department of Radiation Oncology, Gent, Belgium; 16Università degli Studi di Milano, Department of Oncology and Hemato-oncology, Milan, Italy; 17University Medical Center Hamburg-Eppendorf , University Cancer Center Hamburg (UCCH), Hamburg, Germany

Show Affiliations
Purpose or Objective

Using data from an international prospective cohort study of prostate cancer (PCa) patients receiving radical radiotherapy (RT), this analysis aims to estimate α/β ratios for individual urinary toxicity (tox) endpoints: grade 2+ (G2+) urinary frequency, G2+ urinary incontinence and G1+ haematuria. Owing to a previously suggested consequential component of late bladder damage, we also considered the impact of including the total treatment time in NTCP models.

Material and Methods

Non-metastitic PCa patients (pts) were enrolled in 8 countries (04-2014/03-2016). RT was prescribed according to local regimens, but centres used standardised data collection (including baseline symptoms). Tox was scored using CTCAE. Pts in the study had full 3D dosimetric information; we used solid bladder DVHs. Data were available for 1009 pts.

We fitted the probability of late urinary tox within 24 months with the Logit-EUD sigmoid model, explicitly including the α/β ratios and also allowing a term for the impact of total treatment time. The general expression for the NTCP model is in fig 2a. Four parameters describe the model (EUD50, k, n, α/β). A fifth parameter γ was needed for RT time correction. We used the Maximum Likelihood method (Optimization Toolbox, Matlab) to obtain the best estimates of the model parameters.

We compared models including the new estimates of α/β with models with α/β=3Gy (conventional value for late tox).

Results

The cohort included 678 conventionally fractionated pts and 331 hypofractionated pts (Fig 1a). Fig 1b shows the incidence of the tox endpoints within the different subcohorts and Fig 1c the distribution of toxicity events as a function of dose and dose/fraction. We found a consequential effect between acute and late tox for all endpoints (fig 2b).

 

Details on model parameters are in fig 2c. For frequency and incontinence, the late bladder α/β estimates were low (without correction for RTtime), always arriving at the lower allowed boundary, with the inability to converge to a set of parameters. We chose to stop optimisation at α/β =0.3 Gy, which already indicates an extreme effect of fraction size. When including treatment time correction, α/β was 1.4 Gy for frequency and 3 Gy for incontinence, with γ=0.9 and 0.8, respectively. Of note, the volume effect parameter n was 0.06 for incontinence and 0.54 for frequency, pointing at a serial behaviour for the bladder for incontinence and at a more parallel behaviour for frequency. Models with α/β=3Gy had a significantly worse Likelihood and inability to converge in the dose domain (estimates always arriving at the upper allowed boundary). For haematuria, our cohort was unable to discriminate the best α/β ±γ estimate.


Conclusion

We found a greater unexpected impact of hypofractionation on RT induced urinary tox. This could be explained by a bladder α/β<0.3Gy or, radiobiologically more plausible, by introducing a time factor likely to represent a previously hypothesised consequential component of late effect.


This work was funded by REQUITE (EU 7th Framework Programm grant 601826) and RADprecise (ERA-NET ERA PerMed grant ERAPERMED2018-244)